Developer docs
API playgroundTry for free, no card

Search company profiles

Cubit

Full company profile

uuid0098lj2

Namestring
Cubit
Legal namestring
Cubit Diagnostics
Websiteurl
cubitdx.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Cubit Diagnostics is a pre-commercial medical device company developing the Omnio™ multimodal point-of-care diagnostics platform. Founded in 2023 and headquartered in Carlsbad, California, the company is targeting sexually transmitted infection (STI) testing as its lead clinical application through a CT/NG/TV (Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis) molecular assay, with design freeze targeted for Q4 2026 and clinical study in H1 2027.

The company's core technology, the Omnio platform, integrates two complementary diagnostic modalities — nucleic acid amplification-based molecular testing and immunoassay testing — into a single benchtop system intended for use at the point of care. This integration is designed to enable healthcare providers to perform rapid, multiplexed diagnostics on-site rather than sending samples to centralized laboratories, with same-visit clinical decision-making positioned as the primary value proposition. The platform's modular architecture is intended to support an expanding test menu across both modalities.

Cubit operates a pre-commercial hardware-plus-consumables revenue model, with future monetization expected through sales of diagnostic instruments paired with proprietary test cartridges and kits. The planned go-to-market motion is enterprise field sales targeting healthcare providers, urgent care centers, and point-of-care testing environments. Capital raised to date includes a $2.6 million NIH RADx Tech grant and an undisclosed SAFE financing round closed in May 2026, both of which are funding the design freeze and clinical validation milestones. The company currently has 1–10 employees, is privately held, and is not yet generating revenue.

Short descriptiontext

Cubit Diagnostics is a pre-commercial medical device company developing the Omnio™ multimodal point-of-care diagnostics platform, which integrates molecular and immunoassay testing into a single benchtop analyzer, initially targeting STI testing for healthcare providers and point-of-care settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, molecular diagnostics, immunoassay testing, benchtop analyzers, multimodal diagnostics
Industry2 codes
PRIMARYHLAHAOAF
Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Point-of-Care Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Testing Platform and Consumables
TypeHardware Sales
Description

As a diagnostics company developing a point-of-care testing platform, Cubit Diagnostics will generate revenue through the sale of diagnostic instruments and associated consumables (test cartridges/kits) for its Omnio platform. The company is pre-commercial, with design freeze targeted for Q4 2026 and clinical study planned for H1 2027.

pulse2.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Omnio™
Description

A multimodal (molecular and immunoassay) point-of-care diagnostics platform enabling integrated diagnostic testing through a single device.

cubitdx.com
Core offering1 text field

Cubit Diagnostics develops and manufactures the Omnio™ platform, an integrated benchtop point-of-care diagnostics system that combines molecular diagnostics and immunoassay testing modalities in a single device. The company is pre-commercial, with its first molecular assay (CT/NG/TV for sexually transmitted infections) targeted for design freeze in Q4 2026 and clinical study in H1 2027. Revenue, once commercialized, will come from instrument sales paired with consumable test cartridges/kits.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Cubit offers the Omnio™ multimodal diagnostics platform, which integrates two testing modalities—molecular and immunoassay—into a single unified system. The platform is designed for point-of-care use and is being developed with an expanding test menu, including the CT/NG/TV molecular assay currently in late-stage development.

Product and service2 records
1Omnio™ Multimodal Diagnostics Platform
CategoryDiagnostic Instrument Platform
Description

A unified, benchtop point-of-care diagnostics platform that integrates molecular diagnostics and immunoassay testing modalities into a single device, designed for healthcare facilities, clinics, urgent care centers, and point-of-care testing environments requiring rapid, multiplexed diagnostic results.

2CT/NG/TV Molecular Assay
CategoryDiagnostic Consumable / Test Cartridge
Description

A multiplex molecular diagnostic assay designed to detect Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) at the point of care, intended to run on the Omnio platform for healthcare providers offering rapid STI screening.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Abbott (Diagnostics)
TypeBroad incumbent
Description

Abbott provides a broad diagnostics portfolio including the ID NOW rapid molecular POC platform, the m-PIMA HIV/virology POC system, and Alere immunoassay products. Its wide menu and global commercial footprint make it a broad incumbent competing across the same POC testing categories Cubit targets.

TypeDirect peer
Description

Hologic's Panther and Aptima systems are the leading molecular diagnostics platforms for chlamydia, gonorrhea, and Trichomonas testing, primarily in central-lab settings. It defines the gold-standard molecular STI testing workflow that a faster POC platform like Omnio would aim to disrupt.

TypeDirect peer
Description

BioFire, a bioMérieux subsidiary, markets the FilmArray multiplex molecular POC panels (e.g., respiratory, GI, meningitis/encephalitis). Its success in moving syndromic molecular testing out of central labs directly parallels the Omnio strategy of broadening POC molecular menu.

TypeEmerging player
Description

Accelerate Diagnostics sells rapid AST and molecular identification systems aimed at reducing time-to-result in infectious disease diagnostics. It is comparable as a smaller, focused diagnostics player pushing rapid, decentralized testing workflows similar to Omnio's value proposition.

TypeDirect peer
Description

binx health has commercialized the io CT/NG rapid molecular POC test, with FDA clearance for use in CLIA-waived settings. It directly competes with Cubit's planned CT/NG/TV POC molecular assay for STI testing at point of care.

TypeDirect peer
Description

Visby Medical develops a palm-sized PCR-based point-of-care STI testing platform for CT/NG/TV. It is one of the closest direct competitors to Cubit, targeting the same POC STI workflow with a single-use molecular device.

TypeBroad incumbent
Description

QuidelOrtho is a major diagnostics company spanning rapid immunoassay (Sofia, Triage) and molecular products, including Savanna. Its board overlap with Cubit and broad POC menu make it both a potential acquirer and a benchmark for go-to-market execution.

TypeBroad incumbent
Description

QIAGEN provides sample-prep and molecular testing technologies used across STI workflows (e.g., QIAstat-Dx), including in decentralized settings. As a broad life-science tools incumbent expanding into rapid molecular POC, it represents a competitive threat to Omnio's adoption in mid-complexity labs.

TypeDirect peer
Description

Cepheid, owned by Becton Dickinson, sells the GeneXpert molecular point-of-care systems used for CT/NG/TV and other infectious disease testing in CLIA-waived and moderate-complexity settings. It is the dominant POC molecular diagnostics competitor that Cubit's Omnio platform is positioned against.

TypeEmerging player
Description

NOWDiagnostics develops over-the-counter and point-of-care diagnostic tests across multiple analytes using proprietary membrane-based immunoassay and molecular approaches. Its focus on inexpensive, rapid POC testing across modalities makes it a useful emerging-player analog to Cubit's multimodal strategy.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cubit

Point-of-Care Diagnosticscubitdx.com

Cubit Diagnostics is a pre-commercial medical device company developing the Omnio™ multimodal point-of-care diagnostics platform, which integrates molecular and immunoassay testing into a single benchtop analyzer, initially targeting STI testing for healthcare providers and point-of-care settings.

What Cubit does

Cubit Diagnostics is a pre-commercial medical device company developing the Omnio™ multimodal point-of-care diagnostics platform. Founded in 2023 and headquartered in Carlsbad, California, the company is targeting sexually transmitted infection (STI) testing as its lead clinical application through a CT/NG/TV (Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis) molecular assay, with design freeze targeted for Q4 2026 and clinical study in H1 2027.

The company's core technology, the Omnio platform, integrates two complementary diagnostic modalities — nucleic acid amplification-based molecular testing and immunoassay testing — into a single benchtop system intended for use at the point of care. This integration is designed to enable healthcare providers to perform rapid, multiplexed diagnostics on-site rather than sending samples to centralized laboratories, with same-visit clinical decision-making positioned as the primary value proposition. The platform's modular architecture is intended to support an expanding test menu across both modalities.

Cubit operates a pre-commercial hardware-plus-consumables revenue model, with future monetization expected through sales of diagnostic instruments paired with proprietary test cartridges and kits. The planned go-to-market motion is enterprise field sales targeting healthcare providers, urgent care centers, and point-of-care testing environments. Capital raised to date includes a $2.6 million NIH RADx Tech grant and an undisclosed SAFE financing round closed in May 2026, both of which are funding the design freeze and clinical validation milestones. The company currently has 1–10 employees, is privately held, and is not yet generating revenue.

Cubit firmographics

Firmographics
Name
Cubit
Legal name
Cubit Diagnostics
Website
https://cubitdx.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Cubit Diagnostics is a pre-commercial medical device company developing the Omnio™ multimodal point-of-care diagnostics platform, which integrates molecular and immunoassay testing into a single benchtop analyzer, initially targeting STI testing for healthcare providers and point-of-care settings.
Ownership category
akta.pro rank

Cubit industry classification

Industry
Product category
Point-of-Care Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAOAF
Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Point-of-care diagnostics
  • Molecular diagnostics
  • Immunoassay testing
  • Benchtop analyzers
  • Multimodal diagnostics

Where Cubit is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cubit business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Diagnostic Testing Platform and Consumables: As a diagnostics company developing a point-of-care testing platform, Cubit Diagnostics will generate revenue through the sale of diagnostic instruments and associated consumables (test cartridges/kits) for its Omnio platform. The company is pre-commercial, with design freeze targeted for Q4 2026 and clinical study planned for H1 2027.

Go-to-market motion1 record

Marketing channels2 records

Cubit product offering

Product offering

Core offering

Cubit Diagnostics develops and manufactures the Omnio™ platform, an integrated benchtop point-of-care diagnostics system that combines molecular diagnostics and immunoassay testing modalities in a single device. The company is pre-commercial, with its first molecular assay (CT/NG/TV for sexually transmitted infections) targeted for design freeze in Q4 2026 and clinical study in H1 2027. Revenue, once commercialized, will come from instrument sales paired with consumable test cartridges/kits.

Product overview

Cubit offers the Omnio™ multimodal diagnostics platform, which integrates two testing modalities—molecular and immunoassay—into a single unified system. The platform is designed for point-of-care use and is being developed with an expanding test menu, including the CT/NG/TV molecular assay currently in late-stage development.

Differentiator

Problem solved

Functional benefit

Brands

  • Omnio™: A multimodal (molecular and immunoassay) point-of-care diagnostics platform enabling integrated diagnostic testing through a single device.

Products and services

  • Omnio™ Multimodal Diagnostics Platform A unified, benchtop point-of-care diagnostics platform that integrates molecular diagnostics and immunoassay testing modalities into a single device, designed for healthcare facilities, clinics, urgent care centers, and point-of-care testing environments requiring rapid, multiplexed diagnostic results.
  • CT/NG/TV Molecular Assay A multiplex molecular diagnostic assay designed to detect Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) at the point of care, intended to run on the Omnio platform for healthcare providers offering rapid STI screening.

Companies that use Cubit

Customer profile

Segments1 record

Ideal customer profiles1 record

Cubit technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cubit partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Cubit competitors and assessment

Company assessment

Broad incumbents

  • Abbott (Diagnostics): Abbott provides a broad diagnostics portfolio including the ID NOW rapid molecular POC platform, the m-PIMA HIV/virology POC system, and Alere immunoassay products. Its wide menu and global commercial footprint make it a broad incumbent competing across the same POC testing categories Cubit targets.
  • QuidelOrtho: QuidelOrtho is a major diagnostics company spanning rapid immunoassay (Sofia, Triage) and molecular products, including Savanna. Its board overlap with Cubit and broad POC menu make it both a potential acquirer and a benchmark for go-to-market execution.
  • QIAGEN (stat-of-the-art rapid molecular): QIAGEN provides sample-prep and molecular testing technologies used across STI workflows (e.g., QIAstat-Dx), including in decentralized settings. As a broad life-science tools incumbent expanding into rapid molecular POC, it represents a competitive threat to Omnio's adoption in mid-complexity labs.

Direct peers

  • Hologic: Hologic's Panther and Aptima systems are the leading molecular diagnostics platforms for chlamydia, gonorrhea, and Trichomonas testing, primarily in central-lab settings. It defines the gold-standard molecular STI testing workflow that a faster POC platform like Omnio would aim to disrupt.
  • bioMérieux (BioFire): BioFire, a bioMérieux subsidiary, markets the FilmArray multiplex molecular POC panels (e.g., respiratory, GI, meningitis/encephalitis). Its success in moving syndromic molecular testing out of central labs directly parallels the Omnio strategy of broadening POC molecular menu.
  • binx health: binx health has commercialized the io CT/NG rapid molecular POC test, with FDA clearance for use in CLIA-waived settings. It directly competes with Cubit's planned CT/NG/TV POC molecular assay for STI testing at point of care.
  • Visby Medical: Visby Medical develops a palm-sized PCR-based point-of-care STI testing platform for CT/NG/TV. It is one of the closest direct competitors to Cubit, targeting the same POC STI workflow with a single-use molecular device.
  • Cepheid (BD): Cepheid, owned by Becton Dickinson, sells the GeneXpert molecular point-of-care systems used for CT/NG/TV and other infectious disease testing in CLIA-waived and moderate-complexity settings. It is the dominant POC molecular diagnostics competitor that Cubit's Omnio platform is positioned against.

Emerging players

  • Accelerate Diagnostics: Accelerate Diagnostics sells rapid AST and molecular identification systems aimed at reducing time-to-result in infectious disease diagnostics. It is comparable as a smaller, focused diagnostics player pushing rapid, decentralized testing workflows similar to Omnio's value proposition.
  • NOWDiagnostics: NOWDiagnostics develops over-the-counter and point-of-care diagnostic tests across multiple analytes using proprietary membrane-based immunoassay and molecular approaches. Its focus on inexpensive, rapid POC testing across modalities makes it a useful emerging-player analog to Cubit's multimodal strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Cubit social profiles

Digital presence

Cubit financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cubit leadership team

Management profile

Number of profiles

Profiles2 records

Cubit funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cubit M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cubit

What does Cubit do?

Cubit Diagnostics develops and manufactures the Omnio™ platform, an integrated benchtop point-of-care diagnostics system that combines molecular diagnostics and immunoassay testing modalities in a single device. The company is pre-commercial, with its first molecular assay (CT/NG/TV for sexually transmitted infections) targeted for design freeze in Q4 2026 and clinical study in H1 2027. Revenue, once commercialized, will come from instrument sales paired with consumable test cartridges/kits.

Is Cubit a public or private company?

Cubit is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cubit founded?

Cubit was founded in 2023. It employs 1 to 10 people.

Where is Cubit based?

Cubit is headquartered in Carlsbad, United States, in the North America region.

How does Cubit make money?

One revenue line is on record: diagnostic Testing Platform and Consumables.

Who are Cubit's main competitors?

Broad incumbents on record are Abbott (Diagnostics), QuidelOrtho and QIAGEN (stat-of-the-art rapid molecular). Direct peers are Hologic, bioMérieux (BioFire), binx health, Visby Medical and Cepheid (BD). Emerging players are Accelerate Diagnostics and NOWDiagnostics.

Does Cubit have an API?

No public API is recorded for Cubit.

What industry is Cubit in?

Cubit's product category is Point-of-Care Diagnostics. Its primary akta.pro industry code is HLAHAOAF, Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection), with a secondary code of HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Cubit Diagnostics Raises SAFE Financing To Advance Molecular And Immunoassay Platform DevelopmentCubit Diagnostics announced the closing of a SAFE (Simple Agreement for Future Equity) financing round to advance its integrated molecular and immunoassay diagnostic platform. The funding will support design freeze for its CT/NG/TV molecular assay, expected in Q4 2026, followed by a clinical study in H1 2027, as well as expansion of its immunoassay testing menu. The company, based in Carlsbad, California, noted recent board additions to strengthen expertise across diagnostics, regulatory affairs, and commercialization.BioSpaceCubit Diagnostics Closes SAFE Financing to Advance Molecular Assay Development and Expand Immunoassay MenuCubit Diagnostics closed SAFE financing to fund molecular assay design freeze and immunoassay expansion. The company expects design freeze for its CT/NG/TV assay in Q4 2026, leading to a clinical study in 2027. The financing follows a recent board strengthening.FinSMEsCubit Diagnostics Closes SAFE FinancingCubit Diagnostics, a Carlsbad, California-based diagnostics company, has closed a SAFE (Simple Agreement for Future Equity) financing round with undisclosed backers. The proceeds will fund the company's design freeze for its molecular CT/NG/TV assay targeted for Q4 2026 and expansion of its immunoassay program, setting up a clinical study in the first half of 2027. The company also recently consolidated its board of directors with experienced leadership across diagnostics, regulatory, and commercial functions.SdbnCubit Diagnostics Closes SAFE Financing to Advance Molecular Assay Development and Expand Immunoassay Menu – San Diego Biotechnology NetworkCubit Diagnostics closed SAFE financing to fund molecular assay development and expand its immunoassay menu. The company expects to achieve design freeze of its CT/NG/TV molecular assay in Q4 2026, setting up a clinical study in the first half of 2027.Business Wire BlogCubit Diagnostics Closes SAFE Financing to Advance Molecular Assay Development and Expand Immunoassay MenuCubit Diagnostics closed SAFE financing to fund molecular assay development and expand its immunoassay menu. The company expects to achieve design freeze of its CT/NG/TV assay in Q4 2026, leading to a clinical study in 2027. The financing follows a recent board strengthening.Business Wire BlogCubitDx Appoints Robert Bujarski and Mark Paiz to Board of Directors to Support Next Phase of GrowthCubitDx appointed Robert Bujarski and Mark Paiz to its board of directors to support growth. The company is advancing its multimodal point-of-care platform, targeting design freeze in Q4 2026 and clinical validation in 2027.